Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 9541 participants.

Also called NCT05202509

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 9,541 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05202509
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Bulgaria, Canada, China, Croatia, Czechia, Denmark, Finland, Georgia, Germany, Hungary, Israel, Italy, Japan, Jordan, Latvia, Netherlands, Poland, Slovakia, South Africa, Spain, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05202509. Randomized; quadruple masking; primary purpose treatment. Start 2022-02-07 (actual); primary completion 2026-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
Acronym
PREVAIL
Condition
Atherosclerotic Cardiovascular Disease
Intervention (Drug)
Obicetrapib
Intervention (Drug)
Placebo
Lead sponsor
NewAmsterdam Pharma (class: industry)
Collaborator
Monash University (class: other)

Record details

Record id
cardio:ct-nct05202509
Content hash
85a56884c4c567262b859d97cb8696722593b861434e1228ef5acab7260a518d